BCM
ABOS icon

Bronte Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Bronte Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.6K Buy
+10,716
New +$26.5K ﹤0.01% 51

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Bronte Capital Management's ABOS Position: Q2 2026 in Review

Bronte Capital Management opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 10,716 shares worth $28.6K. The stake represents ﹤0.01% of the portfolio and ranks #51 among its holdings.

96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Bronte Capital Management held 10,716 shares of Acumen Pharmaceuticals worth $28.6K as of Q2 2026.
  • Acumen Pharmaceuticals was a new Bronte Capital Management position in Q2 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Bronte Capital Management's portfolio in Q2 2026, its #51 holding.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.